COMPASS PATHWAYS PLC Long-Term Debt, Maturity, Year Five
COMPASS PATHWAYS PLC (CMPS) had Long-Term Debt, Maturity, Year Five of $6.23 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2026-08-05
- 2026-06-30: Long-Term Debt, Maturity, Year Five $6.23M.
- 2026-03-31: Long-Term Debt, Maturity, Year Five $6.15M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2026-06-30 | $6.23M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $6.15M 10-Q · filed 2026-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |